http://hdl.handle.net/2144/953 Obstetrics and Gynecology Tue, 21 May 2013 12:40:57 GMT 2013-05-21T12:40:57Z http://hdl.handle.net/2144/3408 Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Neoplasia in HIV-Infected Men and Women (AMC046) Stier, Elizabeth A; Goldstone, Stephen E; Einstein, Mark H; Jay, Naomi; Berry, J Michael; Wilkin, Timothy; Lee, Jeannette; Panther, Lori; Aboulafia, David; Palefsky, Joel Mon, 11 Oct 2010 00:00:00 GMT http://hdl.handle.net/2144/3408 2010-10-11T00:00:00Z http://hdl.handle.net/2144/3409 Septic Shock, Adult Respiratory Distress Syndrome, and Disseminated Intravascular Coagulopathy Following Midtrimester Genetic Amniocentesis Johnson, J. R.; Stubblefield, P. G.; Hamid, M. A.; Kasznica, J. Background: Midtrimester genetic amniocentesis is a commonly performed procedure, with acknowledgment of some risk to mother and fetus. Case: We present an unusual case of midtrimester genetic amniocentesis with bowel injury and resulting septic shock, adult respiratory distress syndrome, and disseminated intravascular coagulation. A total abdominal hysterectomy and bilateral salpingoophorectomy were required for resolution of sepsis. The patient also required prolonged ventilatory support postoperatively. Conclusion: Although relatively safe, genetic amniocentesis can result in serious morbidity, and attention to technique should be maintained. Sun, 01 Feb 1998 00:00:00 GMT http://hdl.handle.net/2144/3409 1998-02-01T00:00:00Z http://hdl.handle.net/2144/3407 Human Immunodeficiency Virus Type-1 Episomal cDNA in Semen Xu, Chong; Politch, Joseph A; Mayer, Kenneth H; Anderson, Deborah J BACKGROUND. Episomal 2-long terminal repeat (LTR) HIV-1 cDNA, a by-product of HIV-1 infection, is used in clinical trials as a marker for ongoing viral replication. It would be useful to employ 2-LTR cDNA to monitor cryptic HIV-1 infection in the genital tract of men on antiretroviral therapy (ART) to predict the evolution of sexually transmissible drug-resistant HIV-1, but studies thus far have failed to detect this marker in semen. The objectives of this study were: 1) to use a technique that maximizes DNA recovery from HIV-1 infected white blood cells in semen to determine if episomal 2-LTR cDNA is detectable in semen of ART-naïve men with other evidence of genital tract HIV-1 infection, and 2) to compare levels of HIV-1 2-LTR cDNA, RNA, and proviral DNA in semen from HIV-1+ men on ART. RESULTS. Using a somatic cell DNA extraction technique, 2-LTR cDNA was detected by PCR/ELISA in 4 out of 8 semen samples from ART-naïve men selected for other signs of seminal HIV-1 infection (positive controls). Southern blot and DNA sequencing confirmed that the amplified sequences were HIV-1 2-LTR cDNA; copy numbers ranged from 55 to 504 copies/sample. Two semen samples from a cohort of 22 HIV-1-infected men on dual nucleoside therapy, one with and one without detectable seminal HIV-1 RNA, were 2-LTR cDNA positive (336 and 8,560 copies/sample). Following addition of indinavir to the therapy regimen, no semen samples from 21 men with controlled peripheral and seminal viral loads were 2-LTR cDNA positive at 1 and 6 month time points, despite the persistence of HIV-1 proviral DNA+ semen cells and seminal cytomegalovirus (CMV) shedding in some cases. However, one individual who failed indinavir therapy and later developed distinct protease inhibitor (PI) drug resistance mutations in semen, maintained elevated levels of HIV-1 RNA and 2-LTR cDNA in semen. CONCLUSION. 2-LTR HIV-1 cDNA is detectable in semen of HIV-1-infected men. Two men on ART had 2-LTR HIV-1 cDNA in semen, suggesting that this marker may prove to be useful to monitor HIV-1 infection in the genital tract of men on ART to predict the evolution of drug resistance mutations in semen. Tue, 11 Oct 2005 00:00:00 GMT http://hdl.handle.net/2144/3407 2005-10-11T00:00:00Z http://hdl.handle.net/2144/2832 Bisphenol A and Risk Assessment Politch, Joseph A. Sun, 01 Jan 2006 00:00:00 GMT http://hdl.handle.net/2144/2832 2006-01-01T00:00:00Z